News
Retatrutide: Lilly plans a US submission in Q1 2027. What that does and does not tell you
Announcing two further Phase 3 results on 23 July 2026, Lilly said it planned to submit retatrutide to the FDA in the first quarter of 2027. GLPInfo shows this as a company target and keeps its conditional approval scenario in the detail view only.
On 23 July 2026 Eli Lilly announced results from two additional Phase 3 trials of retatrutide and said it planned to submit the medicine to the FDA in the first quarter of 2027 while completing manufacturing-related documentation.
Source: Lilly's triple agonist retatrutide successful in two additional Phase 3 trials (23 Jul 2026)
Retatrutide is an investigational once-weekly injection that acts on three receptors: GIP, GLP-1 and glucagon. It is not approved anywhere.
Source: Lilly's triple agonist retatrutide successful in two additional Phase 3 trials (23 Jul 2026)
GLPInfo records the Q1 2027 plan as a company target, attributed to the sponsor. It is not an application acceptance and not an approval date. A conditional approval scenario, H1 2028 with low confidence in the timing, is available in the timeline's detail view with its assumptions; it is not the headline because it depends on a filing that has not happened.
Source: PDUFA VII commitment letter (September 2021)
For the UK and EU no filing plan has been verified, so the tracker shows Timing unknown and names the next observable milestone: a sponsor statement on regional filing.
Source: International Recognition Procedure
Why it matters
Retatrutide is the most-watched investigational GLP-1 medicine. The gap between a sponsor's filing plan and an approval is where most misleading headlines are written; the tracker labels each step for what it is.
What remains uncertain
- The filing may slip; priority review, if granted, could shorten the review.
- Confidence in timing describes timing only and is never a probability of approval.
On the timeline
About this article. Written by the GLPInfo editorial team with AI assistance from the official sources linked on the page, and approved by the site owner before publication. It has not yet been reviewed by a named clinician. Published 13 Sep 2026. Information, not medical advice: decisions about any medicine sit with you and a qualified prescriber. Spotted an error? Report a correction.